Page 39 - AIH-1-1

Artificial Intelligence in Health Digital and AI strategies for pharmaceutical industry

its accompanying peripherals, it becomes possible to operation ideas, business models, and operation methods
digitize all pertinent data within the value chain. This of logistics enterprises. As a new driving force for the
encompasses the entire spectrum, starting from the raw transformation and upgrading of the logistics industry, AI
material producer and extending to the bioproduct maker, is nurtured in a very favorable development environment,
such as those in the food or pharmaceutical industries, although it has entered the field for a relatively short time [7,8] .
[3]
and ultimately reaching the consumers . The “Industry The digitalization of the pharmaceutical industry
4.0” project is mainly divided into two main themes. The is centered around the collection, storage, and analysis
first is “smart factory,” which focuses on the research of of pharmaceutical data, using the application of digital
intelligent production systems and processes as well as the technology as a means to achieve digital management and
realization of networked, distributed production facilities. deep application of digital technology in business processes
The second is “intelligent production,” which mainly in fields such as medical diagnosis, drug evaluation, and
involves the production logistics management, human- regional pharmaceutical development. Therefore, how to
computer interaction, and application of 3D (digital twin)
technology in the industrial production process of the organically integrate the pharmaceutical industry with
digital technology is an urgent problem to be solved. This
entire enterprise .
[4]
paper aims to achieve the following objectives:
Artificial intelligence (AI) enterprises have entered the (i). To review the digitalization development of the
pharmaceutical industry for a relatively short time . From pharmaceutical industry in the United States, the
[5]
the perspective of the revenue that can be obtained from European Union (EU), and Japan, and to analyze the
the supply side, the market size of Pakistan in the field of current situation of digitalization development in
“AI + Pharma 4.0” was US$ 6.8 million in 2022. With the Pakistan’s pharmaceutical industry.
improvement of technological capabilities, the market size (ii). To propose a development strategy for digitalization
is expected to approach US$ 20.9 million by 2030. In terms in Pakistan’s pharmaceutical industry.
of the application distribution of AI in various aspects of (iii). To discuss AI applications and challenges in the
the pharmaceutical industry, intelligent pharmaceutical pharmaceutical industry of Pakistan.
warehousing and intelligent pharmaceuticals involve a
relatively large-scale application of transportation. The 2. Related works
landing environment for intelligent medical delivery has 2.1. United states
yet to mature, and the current scale is relatively small,
but there is excellent room for imagination in the future. As a leading country in the exploration and development of
The intelligent customer service application scenario is digital technology, the United States health-care industry
[9]
relatively simple, with a minor proportion in each link. The has extensively utilized information technology (IT) . At
process of realizing the conceptualization of Pharma 4.0 is present, the US has made significant contributions to the
shown in Figure 1. construction of digital healthcare by integrating healthcare
and information communication with advanced science
Figure 1 shows the four main steps toward realizing and technology.
the ideal of a Pharma 4.0, including automation of drug
discovery and design processes using machine learning, full Since the 1980s, American medical institutions have
automation of pre-clinical research, AI-powered clinical started to gradually apply IT and automation technology
trials and medical research, and complete digitization of to pharmacies, marking the beginning of digital
[10]
manufacturing and supply chain. However, the key would pharmacy construction . In 2011, the US Food and
be developing general-purpose AI capabilities to learn and Drug Administration (FDA) issued a draft on regulating
[11]
automate tasks across the entire drug development life mobile medical applications . In 2017, the FDA Center
cycle with minimal human intervention. Achieving this for Medical Devices and Radiation Health released the
[12]
level of autonomy is still a long-term goal, but the above digital health innovation action plan . In 2020, the FDA
steps lay the groundwork to reduce human involvement announced the launch of the Digital Health Center of
progressively. Excellence, aiming to promote the strategic development

In recent years, the development foundation and overall of digital health technology and promote digital medical
[13]
environment of Industry 4.0 have undergone significant innovation .
changes . Factors such as the widespread application In terms of digital hospital construction, the information
[6]
of emerging technologies, explosive growth in package industry and medical institutions have been rapidly
numbers, and continuous upgrading of the user experience integrated. For example, the University of Washington
have put forward new demands and challenges for the Medical Center has established a medical information

Volume 1 Issue 1 (2024) 33 https://doi.org/10.36922/aih.1486